# European Observational Study of Enzalutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)

> **NCT02495974** · — · COMPLETED · sponsor: **Astellas Pharma Europe Ltd.** · enrollment: 1763 (actual)

## Conditions studied

- Metastatic Castration Resistant Prostate Cancer

## Interventions

- **DRUG:** enzalutamide

## Key facts

- **NCT ID:** NCT02495974
- **Lead sponsor:** Astellas Pharma Europe Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-08
- **Primary completion:** 2019-02-08
- **Final completion:** 2019-02-08
- **Target enrollment:** 1763 (ACTUAL)
- **Last updated:** 2024-10-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02495974

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02495974, "European Observational Study of Enzalutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02495974. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*